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ABSTRACT Patients with unresectable lung cancer range from those with early-stage or pre-invasive
disease with comorbidities that preclude surgery to those with advanced stage disease in whom surgery is
contraindicated. In such cases, a multidisciplinary approach to treatment is warranted, and may involve
medical specialties including medical oncology, radiation oncology and interventional pulmonology. In
this article we review bronchoscopic approaches to surgically unresectable lung cancer, including
photodynamic therapy, brachytherapy, endoscopic ablation techniques and airway stenting. Current and
past literature is reviewed to provide an overview of the topic, including a highlight of potential emerging
approaches.
Introduction
Lung cancer remains the leading cause of cancer deaths in the United States, responsible for 148869
deaths in 2016 [1]. Fortunately, the incidence is declining in recent years, probably owing to declines in
tobacco use over the past few decades [2]. Nonsmall cell lung cancers (NSCLC) account for up to 80% of
all lung cancer cases in the United States [3]. There are many new advances in the management of
NSCLC, including immunotherapy and targeted therapeutics for patients with identifiable molecular
mutations. However, chemotherapy, radiation and surgical excision remain the mainstays of treatment [4].
Unfortunately, up to 70% of patients have locally advanced or metastatic disease at the time of diagnosis
[3]. Many of these patients are therefore not considered surgical candidates, and thus require a
multidisciplinary approach to manage their disease.
The staging of lung cancer has evolved, with the most updated classification system being the eighth
edition of the tumor, node and metastasis (TNM) staging system put forth by the International
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Association for the Study of Lung Cancer. Patients with advanced-stage disease (stages IIIa–IV) are often
considered surgically unresectable; thus, alternative approaches to treatment are needed. Chemotherapy
and radiation remain the mainstays of treatment for patients who are not surgical candidates; however,
these are often inadequate to fully manage symptoms and complications of advanced disease, particularly
airway obstruction. In such patients, the interventional pulmonologist can play an integral role in the
multidisciplinary approach to lung cancer management.
Bronchoscopic modalities to treat lung cancer have been used for decades and include options such as
ablative techniques and airways prostheses. These techniques are generally considered adjunctive therapies
in patients undergoing curative-intent treatment. However, they are often also indicated for palliation of
symptoms in patients with advanced or incurable disease, particularly those with malignant airway
obstruction. For a subset of patients with early-stage disease, modalities such as photodynamic therapy
(PDT) or brachytherapy may be used as definitive therapy. In this article we review bronchoscopic
techniques for treatment of inoperable NSCLC, with a focus on indications, mechanism of action and
efficacy.
Epidemiology of inoperable NSCLC
Lung cancer remains a major source of morbidity and mortality on the world stage. Cigarette smoke
continues to be the leading cause of lung cancer mortality worldwide, despite reductions in smoking
prevalence over time [2, 5]. The advent of low-dose computed tomography scanning for lung cancer
screening has led to increased detection of earlier stage disease [6]. However, in the United States only a
small portion of eligible patients actually undergo screening, and thus many lung cancer cases are still
diagnosed at a late stage [7, 8].
Limited data exist on the true incidence of unresectable disease in new cases of NSCLC. A recent analysis
using data from the Surveillance, Epidemiology, and End Results database from 2010 to 2016 sought to
assess the incidence of metastatic disease in lung cancer at time of diagnosis and evaluate survival and
prognostic factors [9]. In this analysis, bone was the most common site of metastasis, with an incidence of
nine cases per 100000 people, followed by lung, liver and brain [9]. Most patients with distant metastatic
disease are not surgical candidates [10, 11].
For those patients diagnosed with early-stage disease without distant nodal or organ system metastases,
surgery remains the definitive treatment [12]. In those patients with unresectable disease, chemotherapy
and radiation are the mainstays of treatment [4]. Patients may be deemed unresectable for multiple
reasons, whether it be metastatic disease, size of tumour, involvement of vital structures in the chest and
mediastinum or comorbidities. A significant portion of these patients may suffer from malignant central
airway obstruction or endobronchial disease involving the lobar or segmental bronchi [13]. Endoscopic
management is often required in such patients [14]. Bronchoscopic modalities include ablative therapies
aimed at destroying tumour tissue and restoring airway patency, stents designed to augment airway
patency, and, in selected patients, ablative manoeuvres to definitively treat early-stage disease [15]. The
choice of modality depends on the nature of obstruction (extrinsic, endoluminal or mixed disease) as well
as tumour location [14]. In the following sections we review several such bronchoscopic treatment options.
Photodynamic therapy
PDT refers to the combination of a photosensitising agent and light exposure to treat malignant lesions
[16]. PDT is not new, and its application in lung cancer has been reported dating back to the 1980s [17].
PDT relies on the cytotoxic effects of reactive oxygen species, and the first step is intravenous
administration of the photosensitising agent to the patient, most commonly porfimer sodium [18]. The
guiding principle is that malignant tissues are thought to retain the agent at higher concentration and for
longer duration than normal tissues [19]. After 48–72 h, the light source is then applied to the target
lesion to generate the reactive oxygen species and initiate tumour destruction through cellular death [20–
22]. The light application is commonly performed using a fibreoptic laser diffuser and is applied through
either flexible or rigid bronchoscopy to achieve a target dose of 50–300 J·cm−1 of airway treated [16, 23].
Follow-up bronchoscopy is often required in the days following light application for debridement and
removal of necrotic tissue from the airways [24].
Indications for PDT in NSCLC include patients with symptomatic obstruction of proximal airways as well
as superficial lesions, including early-stage or superficial carcinoma in situ lesions that can be accessed
endoscopically [21]. PDT is often used in combination with systemic chemotherapy or radiation, but here
we focus on endobronchial disease. Patient selection is important, as not all forms of airway obstruction
are appropriate for PDT. Patients with predominantly extrinsic compression should not undergo PDT and
may be more appropriate for alternative therapies such as stenting. In general, the available light sources
are only able to penetrate 5–10 mm, thus lesions longer or deeper than this may not be fully treated with
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PDT [21, 25]. In addition, lesions adjacent to vascular structures carry a risk of complications, including
haemorrhage [26]. Endobronchial ultrasound (EBUS) may be used to inspect the lesion and adjacent
airways for depth of tumour invasion, as well as identification of adjacent structures [27]. Airway patency
beyond the obstruction should be assessed to ensure an appropriate expectation of benefit from the
procedure. Patients with life-threatening obstruction should be offered an alternative approach such as
thermal ablation or mechanical debulking given that the effects of PDT are not immediate.
Numerous studies have demonstrated the safety and efficacy of PDT in NSCLC, although the literature is
heterogenous in terms of patient populations and mostly observational in nature. A summary of pertinent
studies and their outcomes is provided in table 1. HUGH-JONES and GARDNER [28] reported experience in
15 patients with squamous cell carcinoma and airway obstruction, with 75% of patients achieving at least
partial relief of obstruction and complete relief in 25%. KATO et al. [17] reported on PDT in 240 patients
with early-stage bronchogenic carcinoma, with 83% of patients achieving complete remission. MOGHISSI
et al. [20] demonstrated 67% mean improvement in airway obstruction, as well as improvements in lung
function parameters and performance status in 100 patients with malignant airway obstruction, the
majority of whom had NSCLC. Similar, but more dramatic results were reported more recently in a series
by CAI et al. [33]. Studies assessing survival benefit are mixed. MCCAUGHAN and WILLIAMS [24] reported on
175 patients with advanced-stage NSCLC treated with PDT, with 5-month median survival in patients
with stage IV disease. Conversely, MOGHISSI et al. [31] reported separately on PDT treatment in 21 patients
with early central NSCLC and achieved a mean survival of 39 months. MINNICH et al. [32] reported on
PDT treatment in 133 patients, with median survival of 4.4 years, although the patients included were
heterogenous, and PDT was often combined with other treatment modalities including additional ablative
methods. It’s important to note that the majority of these studies were not specifically designed or
powered for survival analysis, and survival largely depended on clinical stage at the time of treatment.
Lastly, a small study comparing PDT to neodymium-doped yttrium aluminium garnet (Nd-YAG) laser in
patients with NSCLC, PDT and laser showed similar efficacy at relieving obstruction, but PDT showed a
slightly longer time to treatment failure [30].
A unique aspect of PDT that deserves special attention is the potential for photosensitivity, which can
occur in patients for up to 4–6 weeks following treatment [22, 34]. However, the reported incidence is low,
and patients should be counselled extensively on the need to avoid direct sunlight during the follow-up
period. PDT remains under investigation in a several different clinical scenarios. PDT can be feasibly be
TABLE 1 Highlighted studies of photodynamic therapy in lung cancer
First author
[reference] Year Study subjects Outcome measure(s) Results
HUGH-JONES [28] 1987 15 patients, squamous
cell carcinoma
Airway obstruction Complete relief of obstruction in 25%, partial relief
in remaining 75%
KATO [17] 1996 240 patients,
bronchogenic carcinoma
Complete remission Complete remission obtained in 83.2% of
early-stage lesions
CORTESE
[29]
1997 21 patients, squamous
cell carcinoma
Complete response Complete response lasting 12 months obtained in
52%
MCCAUGHAN [24] 1997 175 patients with NSCLC Survival, KPS Median survival by clinical stage: IIIa 5.7 months,
IIIb 5.5 months, IV 5 months; KPS had significant
impact on survival
MOGHISSI [20] 1999 100 patients: 90 with
NSCLC, 10 SCLC
Percentage of obstruction, FVC,
FEV1, WHO performance status
67% mean improvement in obstruction,
improvements in FEV1, FVC and performance status
DIAZ-JIMÉNEZ [30] 1999 14 patients with NSCLC Time to recurrence, symptoms
compared to Nd-YAG laser
resection
Similar efficacy, PDT showed longer time to
treatment failure (50 versus 38 days)
MOGHISSI [31] 2007 21 patients, early central
lung cancer, NSCLC
Complete response, survival Complete response in 100%, mean survival
39.3 months
MINNICH [32] 2010 133 patients, NSCLC Mean mMRC dyspnoea scale,
complications, survival
Mean mMRC improved from 3 to 2.7, complications
in 15%, median survival 4.4 years
CAI [33] 2013 30 patients, NSCLC Total response, mean tumour
obstruction, KPS
Total response in 86.7%, mean tumour obstruction
decreased from 90% to 16.7%, mean KPS increased
from 40 to 80
NSCLC: nonsmall cell lung cancer; KPS: Karnofsky Performance Score; SCC: small cell lung cancer; FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 s; WHO: World Health Organization; Nd-YAG: neodymium-doped yttrium aluminium garnet; mMRC: modified Medical
Research Council.
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combined with endobronchial brachytherapy in patients with symptomatic disease who are not candidates
for other therapies [35]. In addition, there is emerging interest in PDT to treat peripheral lung tumours. A
recent animal study demonstrated the feasibility of using navigation bronchoscopy to deliver PDT
treatments to peripheral lesions [36]. Thus, applications for PDT are likely to continue to grow as
bronchoscopic technology evolves.
Brachytherapy
Brachytherapy refers to the delivery of radiation in localised fashion to target tissues in order to avoid
undue exposure to nearby tissues [37]. Endobronchial brachytherapy (EBBT) has been used in NSCLC for
many years as a palliative treatment in those patients not candidates for definitive therapy and as a
definitive treatment in patients with early-stage disease [37]. Although not uniformly available, EBBT is
considered a standard part of the treatment algorithm for patients with symptomatic endobronchial
disease who may not be candidates for external beam radiotherapy or surgical resection [38]. In addition,
similarly to PDT, EBBT is included in the 2013 American College of Chest Physicians guidelines for
treatment of bronchial intraepithelial neoplasia and early stage central lung cancers [25]. EBBT involves
placement of a specialised catheter into the airway adjacent to the target lesion, generally accomplished
using flexible bronchoscopy. The bronchoscope is removed from the airway with the catheter secured in
place, and radiation is delivered to the target tissue after appropriate planning is performed. Both high-
and low-dose formulations have been described, although the high-dose approach is most often employed
in the present day due to better efficacy, and iridium-192 is the most common radioactive material used
[38]. The catheter is removed at bedside once the radiation dose has been delivered and patients are
generally discharged home the same day.
Indications for EBBT include as palliation of symptomatic airway obstruction, and potentially definitive
treatment for superficial malignant or pre-malignant airway lesions. Like PDT, EBBT is best suited for
malignant obstruction that is predominantly endobronchial in nature, though it can be used for some
cases of extrinsic compression when the majority of the lesion is adjacent to the airway. EBBT should not
be used as first-line treatment for those patients who require rapid relief of airway obstruction as treatment
effects will not be fully realised for up to 2–3 weeks [23]. In addition, it is important to acknowledge that
EBBT should not be viewed as equivalent to external beam radiotherapy (EBRT), as multiple head-to-head
studies have shown that EBRT is superior in terms of symptom relief and potentially disease-free survival
in patients with malignant airway obstruction [39, 40]. Thus, the list of indications for EBBT in NSCLC is
narrow in the modern age of cancer therapy.
Major studies demonstrating the effectiveness of EBBT are summarised in table 2. LO et al. [41] reported
on 87 patients with malignant endobronchial disease, 59% of whom showed improvement in symptoms or
degree of obstruction after EBBT. Similarly, the following year another study of 32 patients with
endobronchial disease demonstrated subjective improvements in cough and haemoptysis [42]. A larger
study by TAULELLE et al. [45] included 189 patients, 177 of whom had NSCLC. In this study, 54% had
significant improvement in airway obstruction, 72% had improvement in symptoms, but median survival
was only 5.2 months [45]. Another study of 175 patients, 167 of whom had NSCLC showed 66% with
improvement in symptoms, with mean survival of 6 months [47]. A more recent study by HENNEQUIN et al.
[49] focused on histological response and local disease control. In this study of 106 patients with lung
cancer, 59% of patients showed complete histologic response at 2 months’ follow-up, and 52% had local
control at 5 years, with 49% cause-specific 5-year survival [49]. One of the largest studies, by AUMONT-LE
GUILCHER et al. [51] included 226 patients with NSCLC, with promising results that included 91% of
subjects with complete response at 3-month follow-up and 50% disease-free survival at 5 years. Lastly, one
small prospective study compared Nd-YAG laser treatment to combined laser and EBBT in patients with
inoperable lung cancer and found that the group receiving EBBT plus laser had long duration of symptom
relief (8.5 months versus 2.8 months) and longer progression-free survival (7.5 months versus 2.2 months)
compared to laser alone, highlighting the potential for EBBT to be used as adjunct therapy in certain
patients [53].
These studies suggest that EBBT can be effective at relieving symptomatic airway obstruction and
achieving local disease control in selected patients with NSCLC. The survival data are less compelling, and
studies included patients with various stages of disease. As previously stated, EBBT should not be
considered equivalent to EBRT when that is an available option. Complications of brachytherapy include
those from bronchoscopy itself, catheter dislodgement, and those from local tissue effects of
brachytherapy. One study assessing complications of EBBT in 761 patients showed 5.4% rate of
complications at 3 weeks [54]. The most common was hypoxia, seen in 1.7%, following by haemoptysis in
1.1% [54]. A separate small study showed a much higher rate of bleeding, with massive haemoptysis
occurring in 29% of patients [55]. The authors concluded that contact between the catheter and airway
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wall adjacent to the great vessels substantially increased bleeding risk [55]. Lastly, airway fistulisation with
adjacent structures is a well-recognised complication [56]. Thus, important consideration should always be
given to risks and benefits when contemplating EBBT.
Laser therapy
Patients with unresectable NSCLC presenting with endobronchial disease are often evaluated for
bronchoscopic intervention using local ablative modalities. These range from noncontact modalities
including laser and argon plasma coagulation (APC) to contact methods including electrosurgery and
cryoablation [57]. These techniques are often used in combination with chemotherapy, radiation, and in
select cases airway stenting for immediate relief of obstruction [57]. In this section we briefly review select
modalities available to the interventional pulmonologist.
Laser therapy for cancer treatment has been well described for several decades and involves the application
of light energy to tumour using a catheter in a noncontact fashion [58]. Various lasers are available for
commercial use, and they all differ somewhat in their exact properties regarding depth of tissue
penetration as well as coagulation and vaporisation effects [57]. The most widely used laser in clinical
practice is the Nd-YAG laser, preferred for its excellent coagulation and vaporisation properties. Multiple
series have documented the effectiveness of laser therapy for relief of endobronchial obstruction in benign
and malignant conditions [59, 60]. Laser can be applied through either the flexible or rigid bronchoscope,
TABLE 2 Highlighted studies of brachytherapy in lung cancer
First author
[reference] Year Study subjects Outcome measure(s) Results
LO [41] 1992 87 patients with
malignant endobronchial
disease
Treatment response 59% with improvement in symptoms or airway
obstruction
NORI [42] 1993 32 patients with
endobronchial disease, 30
with lung cancer
Symptom improvement, performance
status
Improvements in cough, haemoptysis and
performance status
PÉROL [43] 1997 19 patients with NSCLC Local control, survival 75% with local control at 1 year; median
survival of 28 months
OFIARA [44] 1997 30 patients with lung
cancer and endobronchial
disease
Radiographic degree of atelectasis,
symptoms, performance status,
bronchoscopic evidence of
obstruction
54% with improvement in atelectasis; 63% with
bronchoscopic improvement in obstruction;
79%, 46% and 33% with improvement in
haemoptysis, cough and dyspnoea, respectively
TAULELLE [45] 1998 189 patients, 177 NSCLC Symptom improvement, survival,
toxicity
Majority had improvement in dyspnoea (54%),
cough (54%), and haemoptysis (76%); median
survival 7 months; 26% with serious toxicity at
18 months
MARSIGLIA [46] 2000 34 patients with NSCLC Disease control, survival, toxicity 85% disease control at 2 years; 78% 2-year
survival; no significant toxicity
KELLY [47] 2000 175 patients with lung
cancer, 167 NSCLC
Survival, symptom improvement Mean survival 6 months, improved survival in
those with symptom improvement; 66% with
symptom improvement
GEJERMAN [48] 2002 41 patients, 33 with
primary lung cancer
Relief of obstruction, symptom
improvement, survival
54% with significant improvement in
obstruction; 72% with significant symptom
improvement; median survival 5.2 months
HENNEQUIN [49] 2007 106 patients with lung
cancer
Histologic response, local control,
survival
59% had complete histologic response at
2 months; 52% with local control at 5 years;
24% 5-year survival, 49% cause-specific 5-year
survival
GUARNASCHELLI
[50]
2010 52 patients with
endobronchial tumours
Symptom improvement, survival,
complications
92% experienced symptom relief; median
survival 7 months; 4% with major complications
AUMONT-LE
GUILCHER [51]
2011 226 patients with NSCLC Treatment response, survival 91% with complete response at 3 months; 68%
and 50% with disease-free survival at 2 and
5 years, respectively
GOLDBERG [52] 2015 98 patients with locally
advanced lung cancer, 93
NSCLC
Survival, quality of life, toxicity 13.4% 1-year overall survival; survival
increased when combined with EBRT,
chemotherapy or CRT; no significant toxicity
NSCLC: nonsmall cell lung cancer; EBRT: external beam radiotherapy; CRT: chemoradiation therapy.
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although in clinical practice rigid bronchoscopy is often preferred [58]. In patients with NSCLC, laser
therapy can be used for treatment of airway obstruction when surgical treatment is precluded. The use of
laser requires a fraction of inhaled oxygen (FiO2) <0.4 to reduce the risk of airway fire, a rare but serious
complication of thermal ablative modalities.
Argon plasma coagulation and electrosurgery
APC and electrosurgery are additional forms of thermal ablation available to the bronchoscopist. Both use
monopolar current via a generator and thus require a grounding pad be placed on the patient for
appropriate dispersion of current. APC is a noncontact form of thermal ablation whereby argon gas is
used as a conduit to transfer heat energy via electrical current to target tissue and was adapted for
endoscopic use after initial applications in open surgery [61, 62]. Often selected for its excellent
haemostatic effects, APC generally has a lower depth of tissue penetration compared to laser [57]. APC is
frequently applied via the flexible bronchoscope and may be used in combination with additional ablative
modalities. APC may be effectively utilised in cases of malignant airway obstruction [63, 64].
Electrosurgery also uses monopolar current to deliver heat energy to target tissue, but is applied via direct
contact with tissue, leading to tissue coagulation and tissue destruction [57, 62]. Electrosurgery may also
be applied via flexible or rigid bronchoscopy, or often using a flexible scope through the rigid
bronchoscope. Common tools include a probe for contact ablation, a snare for tumour removal and a
knife for more precise cutting [57, 62]. Similar to APC, electrosurgery has documented efficacy in
treatment of malignant airway obstruction [65]. Like laser, both APC and electrosurgery require a low FiO2
(<0.4) to avoid risk of airway fire.
Radiofrequency ablation
Radiofrequency ablation (RFA) is an alternative form of thermal ablation that nonetheless relies on heat
energy to cause tissue necrosis and ultimately cell death [66, 67]. RFA has been used successfully to treat
NSCLC via percutaneous application [68]. Recently, a catheter for bronchoscopic application has become
commercially available for use in the United States [69]. In vitro models of bronchoscopic RFA have
suggested efficacy, but as yet there are few published data regarding its effectiveness, although it is gaining
widespread use in clinical practice [70].
Cryotherapy
Cryotherapy, also termed cryoablation, is a contact method that relies on the cytotoxic effects of cold
rather than heat energy and thus differs from the previously discussed ablative modalities [71].
Nonetheless, it may play a role in the patient with unresectable disease [71]. Initial experience with
endobronchial cryotherapy was described in a heterogenous patient population with both benign and
malignant causes of airway obstruction [72]. Cryotherapy is effective at achieving haemostasis and may
prove useful in patients who will not tolerate a lower FiO2 as there is no risk of airway fire. Cryoablation
may be performed feasibly through flexible bronchoscopy, although some operators still prefer use in
conjunction with rigid bronchoscopy. Cryoablation has proven effective at palliating symptoms of airway
obstruction in patients with unresectable lung cancer [73]. Cryoadhesion is a similar technique whereby
the probe is used to adhere to tissue and then remove it from the airway [74]. Spray cryotherapy is a
newer method whereby liquid nitrogen gas is sprayed directly onto target tissues to facilitate tissue
destruction [74]. Use of spray cryotherapy is not yet widespread, although it is quickly gaining popularity
as an ablative technique.
Airway stenting
Airway stents have been used for patients with airway obstruction for decades, dating back to at least the
1960s [75]. They are indicated in a variety of benign and malignant conditions, and are commonly
employed in patients with airway obstruction due to NSCLC. Up to 30% of patients with advanced lung
cancer will develop airway obstruction, thus effective management strategies are crucial [76]. Stents come
in a variety of shapes and sizes, with silicone and self-expanding metallic stents (SEMS) being the two
primary types [77, 78]. Stents may be used in cases of extrinsic obstruction, where the airway is
compressed by tumour in the lung parenchyma or adjacent structures; endoluminal obstruction after
appropriate tumour debulking; or mixed obstruction. One key difference in stent selection is that
commercially available silicone stents require rigid bronchoscopy for placement, whereas SEMS can be
placed using only flexible bronchoscopy and in some cases, fluoroscopy.
Stents are most often employed for palliation of obstruction and are not definitive treatment in and of
themselves. As such, stents are often used in combination with other treatment modalities, including
radiation or other endobronchial ablative techniques [79, 80]. Stents are most commonly deployed in the
trachea or mainstem bronchi [77, 80]. Prior to placing a stent, the operator should first determine that
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airways distal to the site of obstruction are patent, otherwise stenting will be of limited or no benefit. Both
SEMS and silicone stents have demonstrated efficacy in relieving obstruction in patients with malignant
obstruction [78, 81, 82]. Recent attention has focused on placing smaller stents in lobar bronchi for more
distal obstruction. While some patients with benign causes of bronchial obstruction have shown
symptomatic improvement with this technique, there are few data for this technique in patients with
NSCLC and the benefit remains unclear [83, 84].
Patients with respiratory failure due to malignant obstruction deserve special attention. The prognosis of
patients with lung cancer and respiratory has historically been poor. In one study of 81 patients, only 27%
were successfully weaned from mechanical ventilation, and the in-hospital mortality rate was 85% [85].
However, in a separate study, patients with advanced NSCLC and malignant central airway obstruction
treated with therapeutic bronchoscopy had similar survival to patients with advanced NSCLC without
airway obstruction when both received systemic treatment for their malignancy, suggesting a benefit of
bronchoscopy in such patients [86]. A few studies have shown that airway stenting can improve outcomes
for respiratory failure due to malignant airway obstruction. In one small study of 12 patients with NSCLC,
75% could be extubated immediately after bronchoscopy and stent placement, with a median survival of
313 days in those successfully extubated [87]. Another study of 50 patients with respiratory failure due to
malignant central airway obstruction treated with stents suggested improved survival, but this was only
based on comparison with historical controls [88]. Regardless, as in other studies, patients included in this
study showed improvement in symptoms and performance status, thus the role for stenting in eligible
patients is clear.
Complications of stents include migration, formation of granulation tissue, mucostasis and stent fracture
[89]. In general, the rate of complications increases the longer the stent is left in place [89]. In patients
undergoing definitive treatment with chemotherapy and/or radiation in which the stent was used as an
adjunct therapy, close follow-up is warranted to assess for complications and potentially remove the stent
if the patient has shown response to treatment. In those patients in whom stents were placed purely for
palliation pursuing a comfort-based approach, the stents are often left in place indefinitely given short life
expectancy.
Future directions
As with other facets of cancer management, bronchoscopic techniques for NSCLC continue to evolve and
progress. The past few decades have seen numerous innovations in image-guided bronchoscopy to
improve access to peripheral pulmonary nodules. From radial-probe EBUS to electromagnetic navigation
(EMN) bronchoscopy, access to peripheral pulmonary nodules via bronchoscopy has continued to
improve [90]. The newest iteration of image-guided bronchoscopy is robotic bronchoscopy, where
platforms that combine advanced imaging guidance techniques with automated scopes capable of reaching
the periphery of the lungs are used to access lesions previously deemed out of reach of conventional
bronchoscopic techniques [91]. Initial feasibility studies are promising, even when compared to advanced
techniques such as EMN bronchoscopy [91–94]. Robotic and EMN bronchoscopy have traditionally been
employed as diagnostic modalities, but great interest exists in leveraging these technologies to apply
therapeutic modalities for patients with peripheral nodules who cannot undergo surgical resection. For
example, EMN bronchoscopy has been used in animal models to successfully deliver PDT to peripheral
lesions [36]. Likewise, image-guided bronchoscopy has been used to deliver radiofrequency ablation to
peripheral targets in patients with stage I NSCLC who were deemed not surgical candidates, with good
results [95].
Other methods include localised injection, as opposed to systemic administration, of chemotherapeutic
agents into tumour tissue [96]. While this technique has shown feasibility, long-term efficacy is not yet
known. Personalised airway stents are another area of significant interest. Though not studied extensively
in patients with NSCLC, three-dimensional printing to create individualised stents has been used in
selected patients with some success [97, 98]. Likewise, biodegradable stents have been used in limited
patients with benign disease states to prevent complications of stenting in patients who require longer
term airway support [99, 100]. Whether such technologies offer a significant benefit over conventional
airway stents in patients with malignant obstruction remains to be seen.
Conclusion
In conclusion, patients with unresectable NSCLC often require a multimodal approach to treatment that
includes chemotherapy, radiation and potentially bronchoscopic intervention. Bronchoscopic techniques
have evolved over the past several decades. PDT and brachytherapy are widely accepted techniques in
appropriately selected patients. Various endobronchial ablative techniques may be employed for patients
suffering from symptoms of malignant airway obstruction, although they are rarely considered definitive
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therapy. Select patients with malignant airway obstruction may benefit from airway stenting, most likely in
combination with ablative techniques. As technology continues to progress, new modalities continue to
emerge, particularly for patients with peripheral lung tumours who are not surgical candidates. The
treatment landscape for patients should expand as newer investigational techniques become more widely
available.
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